AstraZeneca and Bristol Myers Squibb Held Talks on Combination Valued Near $400bn, Reports Say
The Facts
- AstraZeneca and Bristol Myers Squibb held discussions in recent months about combining the two companies, according to a Financial Times report citing people familiar with the matter.
- A combined company would have a market value of close to $400bn (about £300bn), which would make it the fourth-largest drugmaker in the world by market capitalisation.
- AstraZeneca is the second most valuable listed company in the UK, with a market value of about £196bn (roughly $264bn), while Bristol Myers Squibb, headquartered in Princeton, New Jersey, is worth about $133bn.
- AstraZeneca's London-listed shares fell by roughly 6.5% to 7% on Monday following the reports, making it one of the biggest fallers on the FTSE 100.
- Investors and analysts questioned the logic of the combination, saying AstraZeneca had no obvious need for a transformative acquisition despite potential financial benefits.
- A person familiar with the situation said a potential deal would carry regulatory risk over how US antitrust authorities under the Trump administration might assess it, with Trump focused on domestic investment and expanding US manufacturing.
- Both companies have large oncology businesses, an overlap that analysts and investors expect to attract regulatory scrutiny; Bristol Myers Squibb is best known for its cancer treatments.
- Sources said a deal could materialise soon but could also be delayed or fall apart, and no deal structure has been disclosed.
- AstraZeneca declined to comment on the reports, and Bristol Myers Squibb did not immediately respond to requests for comment.
Context
Why did AstraZeneca's share price fall if it is the potential buyer?
AstraZeneca's London-listed shares dropped about 6.5% to 7% on Monday, the largest decline on the FTSE 100 CNBC,Terra,Yahoo! Finance. Investors and analysts said the UK's biggest drugmaker had no obvious need for a transformative acquisition despite potential financial benefits, and one report described the sell-off as a typical market reaction when a large-cap company is identified as the acquirer in a deal of this scale Terra,Investing.com.
What obstacles could stop the deal?
A person familiar with the situation told Reuters that a transaction would carry regulatory risk because of how US antitrust authorities under President Donald Trump might assess it, noting Trump's focus on domestic investment and expanding US manufacturing Yahoo! Finance,N-tv. Analysts also flagged the overlap between the two companies' oncology franchises as a likely focus of antitrust scrutiny Investing.com. Sources cautioned that the talks could be delayed or fall apart entirely, and no deal structure has been disclosed Yahoo! Finance,Investing.com.
How big would the combined company be, and where do the two firms operate?
The merged group would be valued at close to $400bn, placing it fourth among the world's pharmaceutical companies by market capitalisation Independent,ANSA.it,eldiario.es. AstraZeneca is headquartered in Cambridge, England, and led by chief executive Pascal Soriot Yahoo! Finance,Yahoo! Finance,Guardian. Bristol Myers Squibb is based in Princeton, New Jersey; its UK research team is based at Moreton on the Wirral, with a UK and Ireland commercial head office in Uxbridge Guardian,Yahoo! Finance.
Where Left and Right agree, and where they split
- Where Left and Right agree
- Neither framing sees a need for a deal this size: the overlap and scale are real, and the burden of justifying them sits with management, not skeptics.
- Where Left and Right split
- Who ends up controlling the cancer medicines patients depend on, or whose money executives are spending to buy global rank.
How left and right read it
Two of the world's largest cancer-drug makers discussing a combination worth close to $400bn raises a plain question about who ends up controlling the medicines patients depend on — and their overlapping oncology businesses are the sort of concentration antitrust review is meant to catch. Even investors saw no need for a deal this big. Any scrutiny should turn on competition, not on an administration's appetite for domestic investment and manufacturing.
“The FTSE 100 firm completed a new additional listing on the New York Stock Exchange in June as a result, in a blow to the London markets.” — The Independent
Shares in Britain's second most valuable listed company dropped some 6.5% to 7% on Monday, among the FTSE 100's worst, the moment word of a near-$400bn combination surfaced. Owners questioned the logic and saw no obvious need for a transformative deal. That is the price signal doing its job. Capital belongs to shareholders, not to executives chasing rank among the world's largest drugmakers — let management justify the scale before pursuing it.
“AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb” — The Telegraph
The receipts — all 100 sources
Wire services (7)
Independent coverage (50)
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.